Anti-pd-1 Antibody Treatment
Anti-pd-1 Antibody Treatment - Related Videos
09:11
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
0 Views •
Cited by 2 •
2024
This study illustrates the methodological potential of combining Yttrium-90 Trans-Arterial Radioembolization (Y-90 TARE) with an anti-PD-1 monoclonal antibody as an effective neoadjuvant strategy leading to hepatectomy in hepatocellular carcinoma (HCC) patients with a high initial recurrence risk. It emphasizes the safety, feasibility, and step-by-step procedural guidance of this approach.
06:07
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
0 Views •
Cited by 2 •
2020
We developed a simple flow cytometry assay for evaluating the binding of PD-1–blocking antibodies to T cells, requiring only a drop of peripheral blood from cancer patients.
07:43
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
0 Views •
Cited by 6 •
2018
To expand the ability of laboratories worldwide to assess the eligibility of patients with lung cancer for treatment with pembrolizumab, in a reliable and reproducible manner, we developed an assay that uses the 22C3 antibody concentrate on a widely available immunohistochemical autostainer, for both biopsy and cytology specimens.
07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
0 Views •
2025
This protocol describes a blockade assay for PD-1/PD-L1 inhibitors using surface plasmon resonance technology. It employs a dual-step immobilization strategy and a tailored buffer system to accurately measure response units, facilitating the assessment of blockade rates for compounds or biologics. Additionally, it supports the high-throughput identification of PD-1/PD-L1 inhibitors.
13:01
Anti-Nuclear Antibody Screening Using HEp-2 Cells
0 Views •
Cited by 34 •
2014
Indirect immunofluorescent (IIF) assays have traditionally been used for the detection of antinuclear antibodies (ANA) in human serum. The presence of these antibodies can aid in the diagnosis of systemic autoimmune rheumatic diseases (SARD). This protocol demonstrates how to effectively perform the IIF technique to accurately detect these autoantibodies.
FAQs
The key mechanistic consequence is removal of an inhibitory signal that can limit T-cell activity. When antibody treatment interrupts signaling associated with PD-L1 or PD-L2, T cells may regain functional activity in the tumor microenvironment. This mechanism helps researchers examine how checkpoint regulation affects immune responses against tumors.
The tumor microenvironment is a major setting in which restored T-cell activity must operate. Although blocking PD-1 can improve T-cell function there, the resulting response depends on tumor biology and the activity of immune cells. These local conditions help explain why treatment effects differ among tumors and patients.
Resistance mechanisms can prevent treatment from producing a strong or durable immune response, even when the PD-1 pathway is targeted. Their presence contributes to variation in therapeutic outcomes alongside tumor biology and immune-cell activity. Studying these mechanisms is therefore important for understanding limited responses and improving cancer treatment strategies.
In cancer research, this treatment serves both as a therapeutic approach and as a model for studying immune checkpoint regulation. Investigators use it to examine how altering PD-1-related signaling influences tumor-directed immunity and to support treatment development across multiple tumor types. The work connects molecular immune regulation with cancer therapy.
Researchers should interpret responses in the context of tumor biology, immune-cell activity, and resistance mechanisms rather than treating treatment as uniformly effective. These factors can influence whether immune activity is restored sufficiently to affect a tumor. Considering them helps explain different outcomes across tumor types and experimental or clinical settings.
Immune-related adverse effects matter because restoring immune activity can produce excessive activation as well as antitumor effects. This creates an important balance for cancer research: investigators must consider both the potential for improved tumor-directed immunity and the possibility of harmful immune consequences when evaluating anti-PD-1 treatment.